Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
14 results
  • Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer

25-747          Phase I

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)

  • Gastric (Stomach) Cancer, Sarcoma, Ovarian Cancer

24-169          Phase I

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

  • Bladder Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Endometrial Cancer, Pancreatic Cancer

25-816          Phase I

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary anti-Tumor Activity of STRO-004 in Adults with Refractory/Recurrent Metastatic Solid Tumors

  • Pancreatic Cancer, Esophageal Cancer, Gastric (Stomach) Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Pancreatic Cancer, Liver Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Endometrial Cancer, Bladder Cancer, Sarcoma

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Lung Cancer, Colorectal Cancer, Gastric (Stomach) Cancer

23-340          Phase II

A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors

  • Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer, Bladder Cancer, Kidney Cancer

25-448          Phase II

A Phase 1/2 Study of GEN1286 in Patients with Advanced Solid Tumors

  • Cervical Cancer, Breast Cancer, Gastric (Stomach) Cancer, Metastatic/Advanced Cancer, Head and Neck Cancer

25-075          Phase II

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

  • Gastric (Stomach) Cancer, Esophageal Cancer

24-486          Phase III

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Showing 1 - 10 of 14 results